These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 3030067

  • 1. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
    Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MB.
    Adv Neurol; 1987; 45():111-8. PubMed ID: 3030067
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB.
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [Abstract] [Full Text] [Related]

  • 3. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J.
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [Abstract] [Full Text] [Related]

  • 4. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P, Youdim MB.
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [Abstract] [Full Text] [Related]

  • 5. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G, Elebring T, Nissbrandt H.
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [Abstract] [Full Text] [Related]

  • 6. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J.
    Vopr Med Khim; 1997 Nov; 43(6):482-93. PubMed ID: 9503565
    [Abstract] [Full Text] [Related]

  • 7. The role of MAO in MPTP toxicity--a review.
    Glover V, Gibb C, Sandler M.
    J Neural Transm Suppl; 1986 Nov; 20():65-76. PubMed ID: 3091762
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G.
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [Abstract] [Full Text] [Related]

  • 9. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J.
    Biomed Pharmacother; 1995 Mar; 49(4):187-95. PubMed ID: 7669938
    [Abstract] [Full Text] [Related]

  • 10. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K, Szende B.
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [Abstract] [Full Text] [Related]

  • 11. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
    Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, Wolf AP, Pappas N, Alexoff D, Shea C.
    Synapse; 1994 Oct; 18(2):86-93. PubMed ID: 7839316
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB, Weinstock M.
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [Abstract] [Full Text] [Related]

  • 13. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M, Willoughby J, Glover V, Gibb C.
    J Neural Transm Suppl; 1987 Jan; 25():35-43. PubMed ID: 3123604
    [Abstract] [Full Text] [Related]

  • 14. R-(-)-deprenyl and parkinsonism.
    Yahr MD.
    J Neural Transm Suppl; 1987 Jan; 25():5-12. PubMed ID: 3123605
    [Abstract] [Full Text] [Related]

  • 15. The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Ruggieri S, Stocchi F, Denaro A, Baronti F, Agnoli A.
    J Neural Transm Suppl; 1986 Jan; 22():227-33. PubMed ID: 3097257
    [Abstract] [Full Text] [Related]

  • 16. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G, Földi P, Held G, Székely AM, Knoll J.
    Pol J Pharmacol Pharm; 1986 Jan; 38(1):57-67. PubMed ID: 3020531
    [Abstract] [Full Text] [Related]

  • 17. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB, Finberg JP.
    Adv Neurol; 1987 Jan; 45():127-36. PubMed ID: 3103383
    [No Abstract] [Full Text] [Related]

  • 18. [Discovery of monoamine oxidase forms A and B].
    Squires RF.
    Vopr Med Khim; 1997 Jan; 43(6):433-9. PubMed ID: 9503561
    [Abstract] [Full Text] [Related]

  • 19. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A, McGeer PL.
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [Abstract] [Full Text] [Related]

  • 20. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M.
    J Neural Transm Suppl; 1986 Dec; 22():107-15. PubMed ID: 3097254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.